These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

444 related items for PubMed ID: 26469915

  • 1. Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach.
    Yoon HJ, Sohn I, Cho JH, Lee HY, Kim JH, Choi YL, Kim H, Lee G, Lee KS, Kim J.
    Medicine (Baltimore); 2015 Oct; 94(41):e1753. PubMed ID: 26469915
    [Abstract] [Full Text] [Related]

  • 2. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H, Wang R, Ye T, Luo X, Zhang Y, Li B, Cai D, Shen L, Sun Y, Chen H.
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [Abstract] [Full Text] [Related]

  • 3. RET, ROS1 and ALK fusions in lung cancer.
    Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H, Ishikawa Y.
    Nat Med; 2012 Feb 12; 18(3):378-81. PubMed ID: 22327623
    [Abstract] [Full Text] [Related]

  • 4. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma.
    Lee SE, Lee B, Hong M, Song JY, Jung K, Lira ME, Mao M, Han J, Kim J, Choi YL.
    Mod Pathol; 2015 Apr 12; 28(4):468-79. PubMed ID: 25234288
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.
    Suehara Y, Arcila M, Wang L, Hasanovic A, Ang D, Ito T, Kimura Y, Drilon A, Guha U, Rusch V, Kris MG, Zakowski MF, Rizvi N, Khanin R, Ladanyi M.
    Clin Cancer Res; 2012 Dec 15; 18(24):6599-608. PubMed ID: 23052255
    [Abstract] [Full Text] [Related]

  • 10. Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.
    Reguart N, Teixidó C, Giménez-Capitán A, Paré L, Galván P, Viteri S, Rodríguez S, Peg V, Aldeguer E, Viñolas N, Remon J, Karachaliou N, Conde E, Lopez-Rios F, Nadal E, Merkelbach-Bruse S, Büttner R, Rosell R, Molina-Vila MA, Prat A.
    Clin Chem; 2017 Mar 15; 63(3):751-760. PubMed ID: 28073897
    [Abstract] [Full Text] [Related]

  • 11. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
    Tanaka K, Hida T, Oya Y, Yoshida T, Shimizu J, Mizuno T, Kuroda H, Sakakura N, Yoshimura K, Horio Y, Sakao Y, Yatabe Y.
    Cancer; 2017 May 15; 123(10):1731-1740. PubMed ID: 28177518
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
    Furugaki K, Mochizuki M, Kohno M, Shu S, Harada N, Yoshimura Y.
    BMC Cancer; 2019 Apr 03; 19(1):301. PubMed ID: 30943926
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
    Drilon A, Bergagnini I, Delasos L, Sabari J, Woo KM, Plodkowski A, Wang L, Hellmann MD, Joubert P, Sima CS, Smith R, Somwar R, Rekhtman N, Ladanyi M, Riely GJ, Kris MG.
    Ann Oncol; 2016 Jul 03; 27(7):1286-91. PubMed ID: 27056998
    [Abstract] [Full Text] [Related]

  • 17. Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma.
    Piton N, Ruminy P, Gravet C, Marchand V, Colasse É, Lamy A, Naoures Mear CL, Bibeau F, Marguet F, Guisier F, Salaün M, Thiberville L, Jardin F, Sabourin JC.
    Lab Invest; 2018 Mar 03; 98(3):371-379. PubMed ID: 29251734
    [Abstract] [Full Text] [Related]

  • 18. [Clinical features of 54 cases of lung adenocarcinomas with c-ROS oncogene 1 fusion].
    Cao H, Zheng J, Zhao J, Guo XJ, Zhou JY, Ding W, Zhou JY.
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb 12; 43(2):120-125. PubMed ID: 32062881
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
    Tsai TH, Wu SG, Hsieh MS, Yu CJ, Yang JC, Shih JY.
    Lung Cancer; 2015 May 12; 88(2):208-14. PubMed ID: 25773866
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.